UNSPSC 51314361: Dexchlorpheniramine/dextromethorphan/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314361 Dexchlorpheniramine/dextromethorphan/pseudoephedrine is a Commodity code that encompasses pharmaceutical products, though recent state and local solicitations tagged under this code diverge significantly from its nominal scope. The most recent opportunities focus on naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products rather than the specific combination-drug formulation the code name implies. State and local issuing bodies across health departments, cooperative purchasing alliances, and county health agencies are sourcing pharmaceutical products through competitive bidding processes, including naloxone and drug deactivation systems for emergency response, generic pharmaceuticals through multi-state cooperative arrangements, and exploratory direct contracting models with manufacturers to optimize prescription fulfillment and cost management.

Activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing preliminary market intelligence to inform future formal solicitations rather than a binding competitive bid. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code shows limited recent activity directly aligned to its stated pharmaceutical combination; the opportunities tagged here reflect broader pharmaceutical procurement across public health and cooperative purchasing channels.